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Introduction {#s1}
============

Suicidal behavioris one of the main public health problems worldwide, which include a wide spectrum of self-destructive actions^[@R1]^. Approximately, one million people die by suicide each year worldwide. With a prevalence rate of 0.0145% and suicide accounting for 1.5% of death by all causes, it is the 10th leading cause of mortality worldwide^[@R2]^. The etiology of suicide due to a combined effect of genetic and external factors is not known exactly^[@R3]^. Social factors alone cannot fully explain suicidal behavior. However, some studies have indicated a strong genetic component to susceptibility to suicidal behavior^[@R4]^.

Catechol-O-methyltransferase (COMT) is an enzyme metabolizing noradrenaline in the synaptic cleft^[@R5]^. Association studies of dopamine receptor genes and COMT in schizophrenia and/or ADHD subjects report genetic associations with various domains of cognitive function, including executive function, verbal and working memory, attention, and performance monitoring. Therefore, it was suggested that COMT could also play a role in the susceptibility to suicidal behavior^[@R6],\ [@R7]^. The COMT gene has a common functional polymorphism, val158met (rs4680) variant^[@R8],\ [@R9]^. This polymorphism is due to a G to A transition at codon 158 of the membrane-bound form of COMT, which corresponds to codon 108 of the soluble form of COMT, resulting in a valine (Val) to methionine (Met) substitution^[@R9]^.

The genetic component of suicidal behaviorwas originally founded by family, adoption and twin studies. Its heritability is in the range between 30%--55%^[@R10],\ [@R11]^. A family history of suicide is a strong risk factor for suicide and suicide attempt^[@R11]^. The COMT gene is located on the long arm of chromosome 22 at 22q11; spans 28 kb and contains six exons^[@R9]^. The function of COMT polymorphism in several psychotic conditions, such as schizophrenia, bipolar disorder, major depressive disorder, obsessive-compulsive disorder, and Parkinson's disease, and the putative effects of COMT on suicide have been proposed^[@R12],\ [@R13]^.

Several case-control studies have reported the association between COMT polymorphism and suicide susceptibility^[@R8],\ [@R9],\ [@R18],\ [@R29]^, but the results are inconclusive partially because of the possible small effect of the polymorphism on suicide risk and the small sample in some published study. Therefore, we performed a meta-analysis to derive a precise estimate of this association.

Methods {#s2}
=======

Publication Search {#s2-0-1}
------------------

We searched the electronic PubMed, Scopus, Web of Knowledge, and Google scholar database to identify all case--control studies examined the association between COMT Val158Met (158G/A) polymorphism and suicide risk up to Mar 2017. The keywords were as follows: ''Catechol-O-methyltransferase'', ''COMT gene'', ''COMT Val158Met'', ''COMT 158G/A'', ''rs4680'', ''polymorphism'', ''genotype'', ''variant'', ''mutation'', suicide'', and ''suicide behavior''. Additionally, reference lists of the relevant case-control studies, review, and meta-analysis were reviewed manually to identify additional relevant studies.

Inclusion and Exclusion Criteria {#s2-0-2}
--------------------------------

Studies included in our meta-analysis had to meet all of the following criteria: 1) used case-control study or cohort study; 2) the studies evaluated the associations between the COMT Val158Met (158G/A) polymorphism and suicide risk; 3) studies published in English and Persian; and provided sufficient information for calculation of odds ratio (ORs) with 95% confidence interval (CI). Accordingly, the following exclusion criteria were also considered: 1) those studies that were not designed as case-control or cohort studies; 2) control population including suicide attempter or other similar conditions; 3) there was no available genotype or allele frequency; 4) duplicate of previous publication; and 5) studies not written in English or Persian. Moreover, if multiple studies from the same case series were available, the one including the more individuals was used in the analysis.

Data Extraction {#s2-0-3}
---------------

Information was carefully extracted from all eligible publications independently by two investigators according to the inclusion criteria listed above and data with discrepancies in identification were discussed by all authors. For each included study, the following information was collected: first author's name, year of publication, country of origin, total number of cases and controls, distribution of genotypes and alleles, minor allele frequencies (MAFs), and *P*-value for Hardy--Weinberg equilibrium (HWE). The countries of origin were categorized as Asian, Caucasian, and African.

Statistical Analysis {#s2-0-4}
--------------------

The associations between the COMT Val158Met (158G/A) polymorphism and suicide were measured by odds ratios (OR) with 95% confidence intervals (CI) under the allele model (A vs. G), the homozygote model (AA vs. GG), the heterozygote model (AG vs. GG), the dominant model (AA+AG vs. GG), and the recessive model (AA vs. AG +GG). The heterogeneity assumption was checked by the Q-statistics with *P*-values \< 0.1, and I^[@R2]^ statistics was calculated to quantify the proportion of the total variation across studies due to heterogeneity^[@R14]^. I^[@R2]^ values of 25%, 50%, and 75% were nominally assigned as low, moderate, and high estimates, respectively. When heterogeneity was considered significant, the random-effects model (DerSimonian- Laird approach) was performed. Otherwise, the fixed-effects model (Mantel-Haenszel approach) was used^[@R15]^. The departure from the Hardy--Weinberg equilibrium (HWE) for the control group in each study was tested using an online HWE calculator. The HWE was considered statistically significant when the *P*-value was less than 0.05. Sensitivity analysis was also tested by removing one study at a time to calculate the overall homogeneity and effect size. Publication bias was evaluated by funnel plots and further assessed by Egger's linear regression test^[@R16],\ [@R17]^. All the statistical analyses were performed by comprehensive meta-analysis (CMA) ver. 2.0 (Chicago, IL, USA) software (Biostat, USA). All the *P* values were 2-sided. *P-*value less than 0.05 was considered statistically significant.

Results {#s3}
=======

Characteristics of Studies {#s3-0-1}
--------------------------

Thirty-seven publications fulfilled our search criteria were preliminarily were enrolled. After reading the titles and abstracts, 22 studies with duplicate titles, review, meta-analyses or focused on unrelated condition were excluded. One study was excluded because was not case--control. Finally, 14 case-control studies^[@R8],\ [@R9],\ [@R18]-[@R29]^, on COMT genotypes and suicide risk were identified, including a total of 2353 suicide attempters and 2593 controls from 2000 to 2016 ([Table 1](#T1){ref-type="table"}). All studies were published in English. Among them five studies were in North America (USA, Canada, and Mexico), five in Asia (Taipei, Japan, and North Korea), and six (Germany, Croatia, Slovenia, Finnish Switzerland and France) in Europe. The genotypes in the healthy control group for two studies were not consistent with HWE (*P*\<0.05)^[@R23],\ [@R29]^. Table 2 summarizes the difference of genotypes and alleles frequency between males and females suicide attempters.

###### Main characteristics of studies included in this meta-analysis

  ----------------------------- --------------------------------- ----------------- ------------- ----------- -------------- -------------- ------------- ------- ------- ----- ---- ----- ----- ------- -------
  **First author**              **Country (Ethnicity)**           **Genotyping**\   **Case/**\    **Cases**   **Controls**   **MAFs** ^a^   **HWE** ^b^                                                  
                                                                  **technique**     **Control**                                                                                                          

  **Genotypes**                 **Allele**                        **Genotypes**     **Allele**                                                                                                           

  **GG**                        **AG**                            **AA**            **G**         **A**       **GG**         **AG**         **AA**        **G**   **A**                                  

  Ohara et al\                  Japan\                            RFLP-PCR          12/135        2           7              3              11            13      58      59    18   175   95    0.351   0.627
  1998 ^[@R18]^                 (Asian)                                                                                                                                                                  

  Nolan et al\                  USA & Finnish\                    No available      84/64         28          35             21             91            77      10      31    23   51    77    0.601   0.933
  2000 ^[@R8]^                  (Caucasian)                                                                                                                                                              

  Russ et al\                   USA\                              RFLP-PCR          49/49         9           28             12             46            52      7       26    16   40    58    0.591   0.491
  2000 ^[@R19]^                 (Caucasian)                                                                                                                                                              

  Liou et al\                   Taipei\                           RFLP-PCR          62/188        36          23             3              95            29      98      79    11   275   101   0.268   0.341
  2001 ^[@R20]^                 (Asian)                                                                                                                                                                  

  Rujescu et al 2003 ^[@R21]^   Germany\                          RFLP-PCR          149/328       35          69             45             139           159     78      167   83   323   333   0.507   0.737
                                (Caucasian)                                                                                                                                                              

  Ono et al\                    Japan\                            RFLP-PCR          163/169       68          79             16             215           111     90      61    18   241   97    0.287   0.125
  2004 ^[@R22]^                 (Asian)                                                                                                                                                                  

  Baud et al\                   Switzerland & France(Caucasian)   RFLP-PCR          427/185       124         218            85             466           388     34      107   44   175   195   0.527   0.029
  2007 ^[@R23]^                                                                                                                                                                                          

  Zalsman et al 2008 ^[@R24]^   USA\                              RFLP-PCR          200/119       34          114            53             106           294     27      67    25   121   117   0.491   0.168
                                (Caucasian)                                                                                                                                                              

  Lee et al\                    Korea\                            RFLP-PCR          197/170       94          85             18             273           121     69      85    16   223   117   0.344   0.160
  2011 ^[@R25]^                 (Asian)                                                                                                                                                                  

  Pivac et al\                  Slovenia\                         Sequencing        356/198       78          197            81             353           359     45      97    56   187   209   0.527   0.809
  2011 ^[@R26]^                 (Caucasian)                                                                                                                                                              

  Nedic et al\                  Croatia\                          TaqMan            82/311        9           38             35             56            108     76      170   65   322   300   0.482   0.095
  2011 ^[@R27]^                 (Caucasian)                                                                                                                                                              

  TovillaZárate\                México\                           TaqMan            105/236       34          58             13             126           84      80      112   44   272   200   0.423   0.664
  et al 2011 ^[@R9]^            (Mixed)                                                                                                                                                                  

  Du et al\                     Canada\                           RFLP-PCR          98/72         16          19             14             51            47      22      30    20   74    70    0.486   0.158
  2014 ^[@R28]^                 (Caucasian)                                                                                                                                                              

  Sun et al.\                   China\                            LCR^c^            369/369       218         129            22             565           173     193     161   15   547   191   0.258   0.008
  2016 ^[@R29]^                 (Asian)                                                                                                                                                                  
  ----------------------------- --------------------------------- ----------------- ------------- ----------- -------------- -------------- ------------- ------- ------- ----- ---- ----- ----- ------- -------

^a^Minor allele frequencies, ^b^Hardy--Weinberg equilibrium, ^c^Ligase chain reaction (LCR).

###### Results of meta-analysis for the COMT Val158Met (158G/A) polymorphism and suicide risk

  --------------------------- ------------------------- --------------- ------------ -------------- -------------- -------------- ------------- ------- ------- ----- ----- ----- ----- ------- -------
  **First author**            **Country (Ethnicity)**   **Case/**\      **Cases**    **MAFs** ^a^   **Controls**   **MAFs** ^a^   **HWE** ^b^                                                   
                                                        **Control**                                                                                                                             

  **Genotypes**               **Allele**                **Genotypes**   **Allele**                                                                                                              

  **GG**                      **AG**                    **AA**          **G**        **A**          **GG**         **AG**         **AA**        **G**   **A**                                   

  **Male Attempters**                                                                                                                                                                           

  Ono et al 2004 ^[@R22]^     Japan (Asian)             112/114         43           60             9              146            78            0.348   62      42    10    166   62    0.271   0.457

  Lee et al 2011 ^[@R25]^     Korea (Asian)             70/85           37           26             7              100            40            0.285   26      48    11    100   70    0.411   0.126

  Pivac et al 2011 ^[@R26]^   Slovenia(Caucasian)       269/132         60           156            53             276            262           0.487   25      64    43    114   150   0.568   0.891

  Nedic et al2011 ^[@R27]^    Croatia (Caucasian)       59/253          6            27             26             39             79            0.669   62      141   50    265   241   0.476   0.062

  Du et al 2014 ^[@R28]^      Canada (Caucasian)        35/47           13           16             6              42             28            0.400   15      18    14    48    46    0.489   0.109

  Sun et al.2016 ^[@R29]^     China (Asian)             117/117         70           40             7              180            54            0.230   64      46    7     174   60    0.256   0.737

  Total                                                 662/745         229          325            108            783            541           0.408   254     356   135   864   626   0.420   0.598

  **Female Attempters**                                                                                                                                                                         

  Ono et al 2004 ^[@R22]^     Japan (Asian)             51/55           25           19             7              69             33            0.323   28      19    8     75    35    0.318   0.130

  Lee et al 2011 ^[@R25]^     Korea (Asian)             127/85          57           59             11             173            81            0.318   43      37    5     123   47    0.276   0.416

  Pivac et al 2011 ^[@R26]^   Slovenia(Caucasian)       87/66           18           41             28             77             97            0.557   20      33    13    73    59    0.447   0.926

  Nedic et al 2011 ^[@R27]^   Croatia (Caucasian)       23/58           3            11             9              17             29            0.630   14      29    15    57    59    0.508   0.998

  Du et al 2014 ^[@R28]^      Canada (Caucasian)        14/24           3            3              8              9              19            0.678   7       11    6     25    23    0.479   0.688

  Sun et al. 2016 ^[@R29]^    China (Asian)             252/252         148          89             15             385            119           0.236   129     115   8     373   131   0.259   0.003

  Total                                                 554/540         254          222            78             730            378           0.341   241     244   55    726   354   0.327   0.555
  --------------------------- ------------------------- --------------- ------------ -------------- -------------- -------------- ------------- ------- ------- ----- ----- ----- ----- ------- -------

^a^Minor allele frequencies, ^b^Hardy--Weinberg equilibrium

Pooled Analysis {#s3-0-2}
---------------

[Table 3](#T3){ref-type="table"} listed the main results of the meta-analysis of COMT Val158Met (158G/A) polymorphism and suicide risk. When all the eligible studies were pooled into the meta-analysis of COMT Val158Met (158G/A) polymorphism, there was no significantly increased risk of suicide under all genetic models (A vs. G: OR=1.089; 95% CI: 0.797, 1.488, *P*=0.592; AA vs. GG: OR=1.012; 95% CI: 0.726, 1.411, *P*= 0.943; AG vs. GG: OR=0.958; 95% CI: 0.762, 1.204, *P*= 0.714; AA+AG vs. GG: OR=0.889; 95% CI: 0.669, 1.182, *P*=0.419; and, AA vs. AG +GG: OR=0.980, 95% CI: 0.746, 1.286, *P*= 0.883).

###### Results of genetic comparisons for COMT 158 G/A (COMT Val158Met) polymorphism and suicide.

  ------------------- -------------------- ----------------- ------------------- ---------------- ---------------------- ------- ------- -------
  **Genetic model**   **No. of studies**   **Model**         **Heterogeneity**   **Odds Ratio**   **Publication Bias**                   
  **I** ^2^ **(%)**   ***P*** **value**    **OR (95% CI)**   ***P*** **value**   **P** ~Beggs~    **P** ~Eggers~                         
  **Overall**                                                                                                                            
  A vs. G             14                   Random            91.00               0.001            1.089 (0.797, 1.488)   0.592   0.273   0.696
  AA vs. GG           14                   Random            61.17               0.001            1.012 (0.726, 1.411)   0.943   0.381   0.558
  AG vs. GG           14                   Random            55.72               0.006            0.958 (0.762, 1.204)   0.714   0.443   0.315
  AA+AG vs. GG        14                   Random            74.78               0.001            0.889 (0.669, 1.182)   0.419   0.458   0.722
  AA vs. AG +GG       14                   Random            61.05               0.001            0.980 (0.746, 1.286)   0.883   0.742   0.784
  **Caucasian**                                                                                                                          
  A vs. G             8                    Random            92.04               0.001            0.962 (0.631, 1.467)   0.858   0.901   0.750
  AA vs. GG           8                    Random            75.49               0.001            1.014 (0.611, 1.682)   0.958   0.901   0.877
  AG vs. GG           8                    Random            53.24               0.036            0.916 (0.680, 1.234)   0.566   0.901   0.993
  AA+AG vs. GG        8                    Random            83.63               0.001            0.829 (0.492, 1.397)   0.481   0.901   0.913
  AA vs. AG +GG       8                    Random            75.56               0.001            0.957 (0.650, 1.409)   0.824   0.901   0.573
  **Asian**                                                                                                                              
  A vs. G             5                    Fixed             51.18               0.085            0.966 (0.830, 1.124)   0.652   0.086   0.294
  AA vs. GG           5                    Fixed             0.00                0.424            1.051 (0.712, 1.550)   0.803   0.086   0.239
  AG vs. GG           5                    Fixed             0.00                0.450            0.871 (0.592, 1.282)   0.483   0.806   0.890
  AA+AG vs. GG        5                    Random            92.78               0.001            0.749 (0.311, 1.799)   0.518   0.806   0.966
  AA vs. AG +GG       5                    Fixed             0.00                0.687            1.135 (0.784, 1.644)   0.502   1.000   0.763
  **Mixed**                                                                                                                              
  A vs. G             1                    Fixed             0.00                1.000            0.907 (0.651, 1.262)   0.562   NA^a^   NA^a^
  AA vs. GG           1                    Fixed             0.00                1.000            1.438 (0.688, 3.007)   0.334   NA^a^   NA^a^
  AG vs. GG           1                    Fixed             0.00                1.000            1.753 (0.875, 3.513)   0.114   NA^a^   NA^a^
  AA+AG vs. GG        1                    Fixed             0.00                1.000            1.071 (0.656, 1.747)   0.784   NA^a^   NA^a^
  AA vs. AG +GG       1                    Fixed             0.00                1.000            0.617 (0.317, 1.201)   0.155   NA^a^   NA^a^
  **By HWE** ^b^                                                                                                                         
  A vs. G             12                   Random            91.57               0.001            1.150 (0.787, 1.681)   0.470   0.450   0.872
  AA vs. GG           12                   Random            59.34               0.005            1.065 (0.736, 1.541)   0.738   0.731   0.886
  AG vs. GG           12                   Random            40.93               0.068            1.067 (0.844, 1.348)   0.588   0.837   0.934
  AA+AG vs. GG        12                   Random            75.22               0.001            0.953 (0.678, 1.340)   0.781   0.945   0.899
  AA vs. AG +GG       12                   Random            64.30               0.001            0.964 (0.700, 1.328)   0.824   0.537   0.568
  ------------------- -------------------- ----------------- ------------------- ---------------- ---------------------- ------- ------- -------

^a^Not applicable, ^b^ Hardy--Weinberg equilibrium

Subgroup Analysis {#s3-0-3}
-----------------

Stratified analysis by ethnicity showed no association between COMT Val158Met (158G/A) polymorphism and suicide risk in the Caucasian, Asian and mixed populations. The same results were also revealed by HWE status ([Table 3](#T3){ref-type="table"}). Results of the stratified analysis studies for female and male attempters are summarized in [Table 3](#T3){ref-type="table"}. In the stratified analysis for male attempters, the data on genotypes of the COMT Val158Met (158G/A) polymorphism was available in six studies including 662 cases and 745 controls. However, the COMT Val158Met (158G/A) polymorphism was not significantly associated with suicide risk under all genetic models. For female attempters, the data on genotypes of the COMT Val158Met polymorphism was available in six studies including 554 cases and 540 controls. The COMT Val158Met (158G/A) polymorphism was associated with an increased the risk of suicide under the homozygote model (AA vs. GG: OR=1.829; 95% CI: 1.158, 2.889, *P*=0.010) and the recessive model (AA vs. AG +GG: OR=1.787; 95% CI: 1.195, 2.671, *P*=0.005) in females ([Table 4](#T4){ref-type="table"}). Additionally, there was no association between COMT Val158Met (158G/A) polymorphism and suicide risk by genotyping technique ([Table 4](#T4){ref-type="table"}).

###### Results of genetic comparisons for COMT 158 G/A (COMT Val158Met) polymorphism and suicide.

  ----------------------------- -------------------- ----------------- ------------------- ---------------- ----------------------- ------- ------- -------
  **Genetic Model**             **No. of studies**   **Model**         **Heterogeneity**   **Odds ratio**   **Publication Bias**                    
  **I** ^2^ **(%)**             ***P*** **value**    **OR (95% CI)**   ***P*** **value**   **P** ~Beggs~    **P** ~Eggers~                          
  **By Gender**                                                                                                                                     
  **Male**                                                                                                                                          
  A vs. G                       6                    Random            82.42               0.001            0.972 (0.644, 1.468)    0.894   1.000   0.931
  AA vs. GG                     6                    Random            74.37               0.002            0.950 (0.439, 2.059)    0.898   1.000   0.624
  AG vs. GG                     6                    Random            70.08               0.005            1.028 (0.621, 1.702)    0.913   0.707   0.993
  AA+AG vs. GG                  6                    Random            75.36               0.001            1.000 (0.591, 1.692)    0.999   0.707   0.839
  AA vs. AG +GG                 6                    Random            79.31               0.001            0.923 (0.451, 1.889)    0.827   1.000   0.987
  **Female**                                                                                                                                        
  A vs. G                       6                    Fixed             39.29               0.144            1.137 (0.943, 1.370)    0.180   0.259   0.050
  AA vs. GG                     6                    Fixed             0.00                0.816            1.829 (1.158, 2.889)    0.010   0.707   0.540
  AG vs. GG                     6                    Fixed             13.92               0.325            0.897 (0.690, 1.167)    0.418   1.000   0.218
  AA+AG vs. GG                  6                    Fixed             27.38               0.229            0.996 (0.775, 1.280)    0.977   0.707   0.053
  AA vs. AG +GG                 6                    Fixed             0.00                0.735            1.787 (1.195, 2.671)    0.005   0.707   0.791
  **By Genotyping Technique**                                                                                                                       
  **RFLP-PCR**                                                                                                                                      
  A vs. G                       9                    Random            93.20               0.001            1.169 (0.715, 1.911)    0.534   0.348   0.842
  AA vs. GG                     9                    Fixed             34.53               0.142            0.954 (0.739, 1.231)    0.716   0.916   0.460
  AG vs. GG                     9                    Random            54.08               0.026            0.959 (0.709, 1.296)    0.784   0.465   0.438
  AA+AG vs. GG                  9                    Random            78.01               0.001            0.851 (0.566, 1.279)    0.437   0.916   0.876
  AA vs. AG +GG                 9                    Fixed             21.66               0.250            0.962 (0.780, 1.187)    0.720   0.602   0.740
  **TaqMan **                                                                                                                                       
  A vs. G                       2                    Random            90.89               0.001            1.366 (0.608, 3.067)    0.450   NA^a^   NA^a^
  AA vs. GG                     2                    Random            91.21               0.001            1.765 (0.280, 11.120)   0.545   NA^a^   NA^a^
  AG vs. GG                     2                    Fixed             0.00                0.356            1.391 (0.908, 2.132)    0.129   NA^a^   NA^a^
  AA+AG vs. GG                  2                    Random            74.50               0.048            1.603 (0.669, 3.840)    0.290   NA^a^   NA^a^
  AA vs. AG +GG                 2                    Fixed             91.98               0.001            1.339 (0.302, 5.933)    0.701   NA^a^   NA^a^
  ----------------------------- -------------------- ----------------- ------------------- ---------------- ----------------------- ------- ------- -------

^a^Not applicable

Sensitivity Analysis {#s3-0-4}
--------------------

To evaluate the robustness of the association results, the meta-analysis was performed repeatedly with each study removed. No individual study significantly affected the pooled ORs. Sensitivity analysis was performed based on HWE, and the corresponding pooled ORs were not materially altered, indicating that our results were statistically robust.

Publication bias {#s3-0-5}
----------------

Publication bias was qualitatively examined using the funnel plots and quantitatively estimated by Begg's test and Egger's test. For all genetic models, the shapes of the funnel plots did not reveal any evidence of obvious asymmetry ([Figure 1](#F1){ref-type="fig"}). These results were further supported by analysis via Egger's linear regression test (A vs. G: P~Beggs~= 0.273, P~Eggers~= 0.696; AA vs. GG: P~Beggs~= 0.381, P~Eggers~= 0.558; AG vs. GG: P~Beggs~= 0.443, P~Eggers~= 0.315; AA+AG vs. GG: P~Beggs~= 0.458, P~Eggers~= 0.722; and AA vs. AG +GG: P~Beggs~= 0.742, P~Eggers~= 0.784, [Table 1](#T1){ref-type="table"}).
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Discussion {#s4}
==========

To date, the association between COMT Val158Met polymorphism and suicide remains controversial because the reports include both positive and negative findings^[@R9],\ [@R30]^. Several large studies in the USA, Germany, Slovenia, and Croatia suicide attempter cases found no evidence for an increased risk of suicide^[@R21],\ [@R24],\ [@R26]^. These epidemiological studies results are inconsistent because this association was found in presence of the COMT Met allele in the male and female suicide attempters and diagnosed with different mental and mood disorders such as schizophrenia and alcohol dependency.. These differences among studies might be explained by the different diagnostic entities used. Therefore, the main limitation could be that the genetic association studies on COMT 158G/A polymorphism have been performed in different ethnicity and may be different criteria have been applied in the studies to define suicidal behavior, which reduces power to find consistent results^[@R21],\ [@R24],\ [@R31]^.To the best knowledge, the present meta-analysis is the most comprehensive and accurate meta-analysis assessed the association between the COMT 158G/A (COMT Val158Met) polymorphism and suicide risk.‏ Our results did not show any‏ significant association between the COMT Val158Met polymorphism and suicide in overall. Several issues should be further discussed to address the negative results. However, for most 14 studies involved, when they were individually removed from the analysis, the association between COMT Val158Met polymorphism and suicidal behavior was not significant still. Thus, the evidence for an association between COMT and suicidal behavior was robust.

Our results were consistent with a more recent meta-analysis on COMT Val158Met and suicide risk. Eleven case--control studies and one case-only study were included on COMT Val158Met polymorphism^[@R9]^. COMT Val158Met polymorphism was not associated with suicidal behavior risk. However, COMT Val158Met and suicide risk essentially remain an open field, as meta-analysis study not selected healthy controls (with only 875 adult suicide attempters). Therefore, their results' reliability and the number of studies are considerably smaller than that needed to receive the robust conclusions^[@R32]^. Moreover, compared with their meta-analysis, subgroup analysis by ethnicity and gender were also carried out. In our meta-analysis, the COMT Val158Met polymorphism was associated with suicide risk in females.

Interestingly, when all the eligible studies were pooled into male and gender subgroups analysis, only in female subgroup increased risk for suicide was found. However, there was an imbalance in gender distribution, with more males in attempters than females. None of the genetic models showed association with male susceptibility, suggesting that COMT 158G/A (COMT Val158Met) manifest female specific influences on suicide attempt. Estrogen in females modulates neurotransmission and neuronal excitability of catecholaminergic systems and increases the concentration of dopamine in the synaptic gap, leading to the different influence of dopamine on emotion and motivation among male and females ^[@R33],,[@R34]^. In addition, gender-related differences in suicide behavior might be due to the fact that COMT 158G/A (COMT Val158Met) polymorphism may differently influence personality traits that presumably affect suicide behavior^[@R35],\ [@R36]^. However, we were unable to conduct accurate more analyses of COMT polymorphisms by gender subgroup for insufficient data, thus the existence of gender-specific influences on suicide in this meta-analysis remains unclear. In this meta-analysis the female specificity in effect of the COMT 158G/A (COMT Val158Met) polymorphism on suicide attempt could be a chance finding, this result is inconsistent with gender differences in the dopamine system^[@R37]^. Further examination in the included eligible case-control studies in the gender subgroups showed significant differences between cases and controls numbers in male and female subgroups.

In interpreting results of this meta-analysis, some limitations should be acknowledged. First, not all the eligible studies were collected; the sample size of the included studies was large enough by ethnicity, especially in non-Caucasian and Asian populations. Therefore, there was a lack of statistical power to evaluate better the association between COMT 158G/A (COMT Val158Met) polymorphism and suicide, especially in subgroup analysis. Second, due to limited individual data, a more precise analysis on other covariates such as age, number of suicide attempts, and environmental factors were not performed. Third, since the genotypes frequency of COMT 158G/A polymorphism not mentioned by gender of suicide attempters in all studies, we only evaluated the eligible studies for gender subgroups. Finally, as suicide is a complex trait, gene-gene and gene-environment interactions were not analyzed. Specific environmental and lifestyle factors will alter the associations between gene polymorphisms and suicide susceptibility. Therefore, it is necessary to evaluate the roles of lifestyles in suicide.

Conclusions {#s5}
===========

The present meta-analysis is the most comprehensive and accurate meta-analysis assessed the association between the COMT 158G/A (COMT Val158Met) polymorphism and suicide risk. COMT Val158Met polymorphism was not associated with suicide risk in overall population. However, subgroup analysis by gender showed that COMT Val158Met polymorphism was strongly associated with suicide risk in the female subgroup. More comprehensive studies and larger samples are necessary to determine conclusively an association of COMT 158G/A (COMT Val158Met) with suicidal behavior.
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Highlights {#box1}
==========

-   The COMT Val158Met polymorphism is not significantly associated with suicide risk in overall analysis.

-   Stratified analysis showed no association between COMT Val158Met polymorphism and suicide by ethnicity.

-   The COMT Val158Met polymorphism does appear to be of major importance in the susceptibility of suicide in females
